CN107574248A - A kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method - Google Patents
A kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method Download PDFInfo
- Publication number
- CN107574248A CN107574248A CN201710893999.0A CN201710893999A CN107574248A CN 107574248 A CN107574248 A CN 107574248A CN 201710893999 A CN201710893999 A CN 201710893999A CN 107574248 A CN107574248 A CN 107574248A
- Authority
- CN
- China
- Prior art keywords
- galnt2
- cell lung
- lung cancer
- small cell
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to detection kit technical field, more particularly to a kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method, the kit includes the PCR primer pair of amplification GALNT2 genes and amplification house-keeping gene GAPDH PCR primer pair.Present invention firstly discovers that there is significant difference in transcriptional expression level of the GALNT2 genes in non-small cell lung cancer and Carcinoma side normal tissue, GALNT2 expression can be very good to judge the prognosis of Patients with Non-small-cell Lung simultaneously, and Cox multinomial logistic regressions confirm that GALNT2 can be as the index of non-small cell lung cancer independent judgment prognosis.The expression of GALNT2 gene transcription levels is detected, can be with auxiliary diagnosis non-small cell lung cancer and prediction patient's prognosis situation.
Description
Technical field
The invention belongs to detection kit technical field, and in particular to a kind of non-small cell lung based on GALNT2 genes
Cancer auxiliary diagnosis, prognostic evaluation kit and its application method.
Background technology
Lung cancer is current most common in the world, maximum to human health and life threat tumour.Non-small cell lung cancer is made
For incidence of disease highest cancerous lung tissue type, because early stage lacks typical clinical symptom, almost 70% non-small cell lung cancer is suffered from
Person is at the beginning of diagnosis with regard to oneself through entering late period or being shifted.One global tumour data survey is shown, is sent out newly
Tumor cases in, lung cancer occupies 17%, and in cancer-related death, lung cancer occupies 23%, occupy tumour correlation
First of property death.Therefore, new Diagnosis of Non-Small Cell Lung and prognostic factor how are found, and excavates its potential therapeutic value still
So the hot issue studied at present, clinician and scientific research personnel urgently need to search out it is economical, convenient, accurately diagnose
And prognostic indicator.
Glycosylation is the most common posttranslational modification of protein, and Aberrant glycosylation is the mark of most of human cancers, and
Many cellularities, including cell propagation are influenceed, apoptosis, breaks up, converts, migrate, invasion and immune response.Mammal be present
Two kinds of main Types of protein glycosylation in cell：N connections connect with O.Polypeptide-N- acetylamino galactosamines transferase 2
(polypeptide N-acetylgalactosaminyltransferase 2, GALNT2) is polypeptide-N- acetylaminos half
A member of galactosyltransferase family, it may take part in the O- glycosylations during immunoglobulin is formed.Meanwhile GALNT2 may shadow
The level of triglycerides is rung, take part in the occurrence and development of diabetes B and Partial tumors.GALNT2 is it has been reported that participate in oral cavity
The occurrence and development of squamous carcinoma, liver cancer and oophoroma etc., but its expression and clinical meaning in non-small cell lung cancer there has been no
Relevant report.
The content of the invention
Invention broadly provides a kind of non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation reagent
Box and its application method, find GALNT2 genes normal portions transcriptional expression by Patients with Non-small-cell Lung tumor locus and cancer
Significant difference be present in level.Compared with normal structure, GALNT2 genes are expressed in non-small cell lung cancer tumor tissues on significantly
Adjust, can be with diagnosing non-small cell lung cancer by detecting the expression of GALNT2 gene transcription levels.Meanwhile according to GALNT2
Expression, it can be estimated that patient's prognosis situation.Its technical scheme is as follows：
A kind of non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit, including amplification
The PCR primer pair of GALNT2 genes, the primer pair are：
Forward primer sequence is 5 '-ACCAGGTGGAGAGTGATAAGC-3 ', such as SEQ ID NO：Shown in 1；
Reverse primer sequences are 5 '-TCCTCAGGATCATTGCTGTAGTC-3 ', such as SEQ ID NO：Shown in 2.
Preferably, the kit also includes amplification house-keeping gene GAPDH PCR primer pair, and the primer pair is：
Forward primer sequence is 5 '-GCACCGTCAAGGCTGAGAAC-3 ', such as SEQ ID NO：Shown in 3；
Reverse primer sequences are 5 '-TGGTGAAGACGCCAGTGGA-3 ', such as SEQ ID NO：Shown in 4.
Preferably, the kit also includes SYBR Green PCR systems, and the SYBR Green gather
Polymerase chain reaction system includes PCR buffer solutions, dNTPs, SYBR Green fluorescent dyes, is loaded without enzyme water and fluorescent quantitation
Plate.
Preferably, the kit also includes RNA extracts reagents, and the RNA extracts reagents include Trizol, chloroform, different
Propyl alcohol, 75% ethanol and without enzyme water.
Preferably, the kit also includes the system that mRNA reverse transcriptions are cDNA, the reverse transcription system including gDNA
Eraser, gDNA Eraser Buffer, T repeat oligonucleotides Oligo (dT), inverse transcription reaction liquid, reverse transcriptase and
dNTPs。
A kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method,
Comprise the following steps：
(1) flesh tissue of acquisition is subjected to RNA extractings after liquid nitrogen processing grinding；
(2) by the RNA reverse transcriptions extracted into corresponding cDNA；
(3) cDNA after reverse transcription is subjected to the fluorescent quantitative PCR to GALNT2 and GAPDH genes；
(4) using GAPDH as internal reference, the Ct values each reacted are recorded, testing result is represented with Δ Ct, wherein Δ Ct=
CtGene-CtGAPDH。
Application of the GALNT2 genes in non-small cell lung cancer auxiliary diagnosis, prognostic evaluation kit is prepared.
Using such scheme, the present invention has advantages below：
(1) present invention firstly discloses the occurrence and development of GALNT2 genes and non-small cell lung cancer are closely related, GALNT2
Gene is expected to the molecular marker as diagnosing non-small cell lung cancer, and is the molecule machine of research non-small cell lung cancer progression of disease
Reason provides new thinking；
(2) GALNT2 genes by Patients with Non-small-cell Lung tumor locus with cancer normal portions transcriptional expression level deposit
In significant difference, compared with Carcinoma side normal tissue, GALNT2 genes are in the expression significantly of Patients with Non-small-cell Lung tumor locus
Adjust, by detecting the expression of GALNT2 gene transcription levels, can be contained with diagnosing non-small cell lung cancer so as to prepare
There is the non-small cell lung cancer auxiliary diagnostic box of GALNT2 genes, diagnosed using the mode for detecting gene transcription level expression non-
The method of ED-SCLC is more sensitive more special, is advantageous to the diagnosis of disease early stage；
(3) present invention confirms that height that GALNT2 genes express in non-small cell lung cancer and patient's prognosis are direct first
Correlation, compared with low expression GALNT2 patient, life span substantially reduces height expression GALNT2 Patients with Non-small-cell Lung.
By detecting the expression of GALNT2 transcriptional levels, the prognosis situation of Patients with Non-small-cell Lung can be estimated, so as to prepare
Non-small cell lung cancer prognostic evaluation kit containing GALNT2 genes, it is pre- more precisely, more can objectively to judge patient
Afterwards；
(4) present invention also prompting can block non-small cell lung cancer progression of disease by intervening GALNT2 expression, and it has
Possibly as the specific target spot of non-small cell lung cancer future targeted therapy, new think of is provided for the treatment of non-small cell lung cancer disease
Road.
Brief description of the drawings
Fig. 1 is GALNT2 gene mRNAs in TCGA databases in 110 non-small cell lung cancer Carcinoma side normal tissues and 1016
Expression in example cancerous tissue；
Fig. 2 is non-small for diagnosing based on GALNT2 gene mRNA expression situations in TCGA databases, the GALNT2 of drafting
The ROC curve of cell lung cancer；
Fig. 3 is expression feelings of the GALNT2 gene mRNAs in clinical samples source in 60 pairs of Patients with Non-small-cell Lung tissues
Condition；
Fig. 4 is non-small for diagnosing based on clinical samples source GALNT2 gene mRNA expression situations, the GALNT2 of drafting
The ROC curve of cell lung cancer；
Fig. 5 is in TCGA non-small cell lung cancer database, and the existence drawn based on GALNT2 gene mRNAs height is bent
Line；
Fig. 6 is the life that the GALNT2 gene mRNAs height of the non-small cell lung cancer based on 60 pairs of clinical samples sources is drawn
Deposit curve；
Fig. 7 is that CCK-8 experiments confirm that tumor cell proliferation capability result figure can be suppressed by reducing GALNT2 expressions；
Fig. 8 is that Transwell experiments confirm that tumor cell invasion capability result can be suppressed by reducing GALNT2 expressions
Figure.
Embodiment
Specific embodiment
Experimental method in following examples is conventional method unless otherwise required, involved experiment reagent and material
Material is routine biochemistry reagent and material unless otherwise required.
First, TCGA databases contrast GALNT2 differential expressions in Patients with Non-small-cell Lung cancer and Carcinoma side normal tissue
The plan of oncogene collection of illustrative plates (The Cancer Genome Atlas, TCGA) project team is initially swollen by American National
Knurl research institute (The national cancer institute, NCI) and American National human genome research institute (The
National human genome research institute, NHGRI) composition, and develop into a very big data
Research platform.Non-small cell lung cancer sample mainly includes lung squamous cancer and adenocarcinoma of lung sample in TCGA, data source in
(https://genome-cancer.ucsc.edu), wherein Carcinoma side normal tissue has included 110, and cancerous tissue has included 1016
Example sample.RNA-seq result of the GALNT2 gene transcription levels result from Illumina HiSeq microarray datasets.Fig. 1 is
Expression feelings of the GALNT2 gene mRNAs in Carcinoma side normal tissue (Normal) and cancerous tissue (Cancer) in TCGA databases
Condition.As shown in figure 1, compared with Carcinoma side normal tissue, GALNT2 genes expression in cancerous tissue significantly rises (P<
0.0001)。
2nd, based on GALNT2, differential expression draws Diagnosis of Non-Small Cell Lung ROC curves in TCGA
GALNT2 expressions based on above-mentioned TCGA samples non-small cell lung cancer sample cancerous tissue and cancer beside organism, are painted
Make the ROC curve for diagnosing non-small cell lung cancer.In ROC evaluating method for curve, the area value AUC under ROC curve is big
In the case of 0.5, closer to 1, illustrate that diagnosis effect is better.AUC has relatively low accuracy at 0.5~0.7, and AUC exists
There is certain accuracy when 0.7~0.9, there is high accuracy when AUC is more than 0.9.As a result as shown in Fig. 2 GALNT2 diagnosis are non-
Area (AUC) is 0.853 under the ROC curve of ED-SCLC, i.e. diagnosis has certain accuracy.
3rd, GALNT2 differential expressions in clinical tissue pattern detection lung cancer tissues and cancer beside organism
It is normal by Non-Small Cell Lung Carcinoma and the cancer of pairing that affiliated hospital of Zhengzhou University first, which is collected, through pathological diagnosis
Tissue samples 60 are right.RNA extractions and reverse transcription are carried out to these samples, the cDNA obtained to reverse transcription carry out GALNT2 and
The quantitative fluorescent PCR amplification of GAPDH genes.As a result it is as shown in Figure 3.From the figure 3, it may be seen that GALNT2 genes are in non-small cell lung cancer
Relative expression levels significantly rise compared with expression in Carcinoma side normal tissue in cancerous tissue
(P<0.0001)。
4th, based on GALNT2, differential expression draws Diagnosis of Non-Small Cell Lung ROC curve in clinical tissue
60 pairs of Non-Small Cell Lung Carcinoma sample GALNT2 expressions based on above-mentioned collection, draw non-small for diagnosing
The ROC curve of cell lung cancer.As a result as shown in figure 4, area (AUC) is under the ROC curve of GALNT2 diagnosing non-small cell lung cancers
0.907, i.e. diagnosis has high accuracy.
5th, GALNT2 expression height draws survivorship curve in TCGA non-small cell lung cancer database
In TCGA databases, 1016 tumor samples are included in non-small cell lung cancer data, what it is with prognosis information is
958.This 958 samples are sorted according to GALNT2 mRNA expressions, high expression group is first 479, and low expression group is
479 afterwards, survivorship curve is drawn, Fig. 5 is the survivorship curve drawn based on GALNT2 gene mRNAs height.Pass through longrank
Test analyzes to obtain P<0.0001, i.e. prognosis is statistically significant.Illustrate in non-small cell lung cancer, height expression GALNT2 patient
Prognosis is significantly worse than low expression GALNT2 patient.
6th, GALNT2 expression height draws survivorship curve in the non-small cell lung cancer tumor tissues in clinical samples source
60 patients of non-small cell lung cancer that clinic is collected carry follow-up information.According to 60 sample GALNT2 mRNA
Expression sorts, and high expression group is first 30, and low expression group is latter 30, draws survivorship curve, and Fig. 6 is based on GALNT2 bases
The survivorship curve drawn by mRNA height.P=0.0061 is analyzed to obtain by longrank test, i.e. prognosis has statistics meaning
Justice.Further confirm that high expression GALNT2 patient's prognosis is significantly worse than low expression in non-small cell lung cancer clinical sample
GALNT2 patient.
7th, CCK-8 experiments confirm that tumor cell proliferation ability can be suppressed by reducing GALNT2 expressions
Choose in vitro culture Lines A549 carry out intervention experiment, after recovery with 37 DEG C, 5%
CO2Cultivated in incubator, 24h is with 2 × 10 before A549 cell transfectings5Individual cell per well is inoculated in 6 well culture plates, when cell reaches
When 60%-80% is merged, with reference to Lipofectamine2000 product descriptions respectively by SiRNA-NC and SiRNA-GALNT2
Transfection changes fresh culture into six orifice plates after transfecting 6h, continues culture and collects two groups of cell dissociations to after 24 hours, meter
Number, is inoculated in 96 orifice plates with every μ L of hole 3000/100, and 10 μ L are added at 0,1,2,3,4 day (d) respectively after cell attachment
CCK-8,37 DEG C is incubated after 1.5h its absorbance of detection at wavelength 450nm.By CCK-8 methods detect cell attachment after 0,1,
2nd, 3,4d OD value, growth curve, as a result as shown in fig. 7, compared with SiRNA-NC groups, middle cell growth rate are drawn
It is decreased obviously (P<0.05) it is inhibited, to illustrate that reduction GALNT2 can breed to A549 cells.
8th, Transwell experiments confirm that tumor cell invasion ability can be suppressed by reducing GALNT2 expressions
Cell is resuspended with the culture mediums of serum-free RPMI 1640 in A549 cell lines after transfecting 24 hours and control group, is adjusted
To 2.5 × 105/ ml cells, 100 μ L are taken to add in the upper chamber hole of Transwell plates, lower room adds 600 μ L and contains calf serum
The culture mediums of RPMI 1640.37 DEG C, 5%CO2Exhaust culture medium after being cultivated 12 hours in incubator, after PBS, formaldehyde room temperature is consolidated
Determine 15min, the cell of upper surface, brazilwood extract dyeing, dry overnight at room temperature are dabbed with cotton swab.Fig. 8 results show, lower
After GALNT2 gene expression, A549 cell invasions ability is significantly suppressed (P<0.05), illustrate that suppressing GALNT2 can suppress
The invasive ability of lung carcinoma cell.
9th, the Cox multinomial logistic regressions of the Non-Small Cell Lung Carcinoma based on 958 TCGA sources
Sex, age, tumor size and GALNT2 expression are included into Cox multinomial logistic regression models, analyze
These factors and the relation of Patients with Non-small-cell Lung prognosis.Analysis result such as table 1.
The Cox multinomial logistic regression results of non-small cell lung cancer of the table 1 based on TCGA sources
The result illustrates that GALNT2 expressions have the value (P of independent judgment prognosis to non-small cell lung cancer<
0.0001)。
Tenth, the preparation and use of the non-small cell lung cancer auxiliary diagnostic box based on GALNT2 genes
1. non-small cell lung cancer auxiliary diagnostic box includes the PCR primer pairs of amplification GALNT2 genes, amplification house keeper's base
Because GAPDH PCR primer to, SYBR Green PCRs system, RNA extracts reagents, mRNA reverse transcriptions be cDNA
System.
Wherein expand GALNT2 genes PCR primer to for：
Forward primer sequence is 5 '-ACCAGGTGGAGAGTGATAAGC-3 ', such as SEQ ID NO：Shown in 1；
Reverse primer sequences are 5 '-TCCTCAGGATCATTGCTGTAGTC-3 ', such as SEQ ID NO：Shown in 2.
Expand house-keeping gene GAPDH PCR primer to for：
Forward primer sequence is 5 '-GCACCGTCAAGGCTGAGAAC-3 ', such as SEQ ID NO：Shown in 3；
Reverse primer sequences are 5 '-TGGTGAAGACGCCAGTGGA-3 ', such as SEQ ID NO：Shown in 4.
The SYBR Green PCRs system includes PCR buffer solutions, dNTPs, SYBR Green fluorescence dye
Expect, without enzyme water and fluorescent quantitation sample-adding plate.
The RNA extracts reagents include Trizol, chloroform, isopropanol, 75% ethanol and without enzyme water.
The system that the reverse transcription is cDNA includes gDNA Eraser, gDNA Eraser Buffer, T and repeats few nucleosides
Sour Oligo (dT), inverse transcription reaction liquid, reverse transcriptase and dNTPs.
2. the detection process of diagnostic kit is as follows：
1) flesh tissue to be measured is ground under liquid nitrogen effect, 1mL Trizol is added in the tissue after fragmentation, are made
Blown and beaten repeatedly with 1mL liquid-transfering gun, be incubated at room temperature 5min, be sufficiently separated nucleoprotein complex；
2) often pipe adds 500 μ L chloroforms, mixing 10 times of turning upside down.After solution is fully emulsified, 5min is stored at room temperature.4
DEG C centrifugation, 12000rpm, 15min；
3) centrifuge tube is carefully taken out from centrifuge, now homogenate is divided into three layers, i.e.,：It is colourless aqueous phase, middle white
Chromoprotein layer and with coloured lower floor's organic phase.Extract water phase transfer is into new centrifuge tube；
4) isometric isopropanol is added into aqueous phase, after the centrifuge tube that turns upside down fully mixes, is stored at room temperature 10min；4
DEG C, 12 000rpm centrifugation 10min, after centrifugation, precipitation occurs in EP bottom of the tube；
5) careful supernatant discarding, the ethanol (being sure not to touch precipitation) of lmL precoolings 75% slowly is added along centrifugation tube wall,
12000rpm, 4 DEG C of centrifugation 5min, supernatant discarding；
6) drying at room temperature precipitation 2-5min, appropriate RNase-free water dissolving precipitation is added, liquid-transfering gun can be used if necessary
Gently piping and druming precipitation；
7) Nanodrop detections RNA concentration and purity are utilized.OD260/OD280 ratios are between 1.80-2.0, explanation
RNA purity meets requirement of experiment；
8) reverse transcription：5 × gDNA Eraser Buffer (2 μ L), gDNA Eraser (1 μ L), RNA (1 μ) are configured first
With RNase-free water mixed systems, totally 10 μ L, 42 DEG C, 2min；By 5 × PrimeScript buffer 2 (4 μ L),
PrimeScript RT Enzyme Mix (1 μ L), RT Primer Mix (1 μ L), RNase-free water (4 μ L) and above-mentioned mixed
Close liquid (10 μ L) to be mixed, PCR instrument, reaction condition are put into after of short duration centrifugation：37 DEG C of reaction 15min, 85 DEG C are reacted 5 seconds, are obtained
Obtain CDNA；
9) it is loaded：Fluorescent quantitation plate is placed on ice, each sample sets 2 multiple holes, by cDNA (4~5 times of dilution, dilution
Afterwards plus 2 μ L), SYBER Green and RCR buffer solutions be mixed every μ L of hole 12, it is laggard to have configured total system per the μ L of hole 8 for primer
Row packing, reduces error；
10) after sample-adding terminates, using PE gloves carefully by fluorescent quantitation plate membrane cover upper sealing panel, centrifugation, bubble is avoided to produce
It is raw；
11) program is set：95℃10min；95 DEG C of 10s, 60 DEG C of 10s, 72 DEG C of 10s, 40 circulation+solubility curves；
12) analysis of experimental data：Using GAPDH as internal reference, the Ct values each reacted are recorded, Ct values are each reaction tube
Interior fluorescence signal reaches the period undergone during the threshold value of setting.Δ Ct=CtGene-CtGAPDH, Δ Ct is smaller to represent that it rises
Beginning copy number is more, and expression is higher.
It will be apparent to those skilled in the art that technical scheme that can be as described above and design, make other various
Corresponding change and deformation, and all these changes and deformation should all belong to the protection domain of the claims in the present invention
Within.
Sequence table
<110>Affiliated hospital of Zhengzhou University first
<120>A kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method
<130> 1
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 1
accaggtgga gagtgataag c 21
<210> 2
<211> 23
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
tcctcaggat cattgctgta gtc 23
<210> 3
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 3
gcaccgtcaa ggctgagaac 20
<210> 4
<211> 19
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 4
tggtgaagac gccagtgga 19
Claims (7)
1. a kind of non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit, it is characterised in that：It is described
Kit includes the PCR primer pair of amplification GALNT2 genes, and the primer pair is：
Forward primer sequence is 5 '-ACCAGGTGGAGAGTGATAAGC-3 ', such as SEQ ID NO：Shown in 1；
Reverse primer sequences are 5 '-TCCTCAGGATCATTGCTGTAGTC-3 ', such as SEQ ID NO：Shown in 2.
2. the non-small cell lung cancer auxiliary diagnosis according to claim 1 based on GALNT2 genes, prognostic evaluation kit,
It is characterized in that：The kit also includes amplification house-keeping gene GAPDH PCR primer pair, and the primer pair is：
Forward primer sequence is 5 '-GCACCGTCAAGGCTGAGAAC-3 ', such as SEQ ID NO：Shown in 3；
Reverse primer sequences are 5 '-TGGTGAAGACGCCAGTGGA-3 ', such as SEQ ID NO：Shown in 4.
3. the non-small cell lung cancer auxiliary diagnosis according to claim 1 based on GALNT2 genes, prognostic evaluation kit,
It is characterized in that：The kit also includes SYBR Green PCR systems, the SYBR Green polymerases
Chain reaction system include PCR buffer solutions, dNTPs, SYBR Green fluorescent dyes, without enzyme water and fluorescent quantitation sample-adding plate.
4. the non-small cell lung cancer auxiliary diagnosis according to claim 1 based on GALNT2 genes, prognostic evaluation kit,
It is characterized in that：The kit also includes RNA extracts reagents, the RNA extracts reagents include Trizol, chloroform, isopropanol,
75% ethanol and without enzyme water.
5. the non-small cell lung cancer auxiliary diagnosis according to claim 1 based on GALNT2 genes, prognostic evaluation kit,
It is characterized in that：The kit also includes the system that mRNA reverse transcriptions are cDNA, the reverse transcription system including gDNA
Eraser, gDNA Eraser Buffer, T repeat oligonucleotides Oligo (dT), inverse transcription reaction liquid, reverse transcriptase and
dNTPs。
6. a kind of non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, the application method of prognostic evaluation kit, it is special
Sign is：Comprise the following steps：
(1) flesh tissue of acquisition is subjected to RNA extractings after liquid nitrogen processing grinding；
(2) by the RNA reverse transcriptions extracted into corresponding cDNA；
(3) cDNA after reverse transcription is subjected to the fluorescent quantitative PCR to GALNT2 and GAPDH genes；
(4) using GAPDH as internal reference, the Ct values each reacted are recorded, testing result is represented with Δ Ct, Δ Ct=CtGene-
CtGAPDH。
Application of the 7.GALNT2 genes in non-small cell lung cancer auxiliary diagnosis, prognostic evaluation kit is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710893999.0A CN107574248A (en) | 2017-09-28 | 2017-09-28 | A kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710893999.0A CN107574248A (en) | 2017-09-28 | 2017-09-28 | A kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107574248A true CN107574248A (en) | 2018-01-12 |
Family
ID=61039990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710893999.0A Pending CN107574248A (en) | 2017-09-28 | 2017-09-28 | A kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107574248A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109628591A (en) * | 2018-12-04 | 2019-04-16 | 南方医科大学南方医院 | Marker for adenocarcinoma of lung prognosis prediction |
| CN110618271A (en) * | 2019-09-29 | 2019-12-27 | 中国医学科学院肿瘤医院 | Method for predicting prognosis of non-small cell lung cancer |
| CN111518890A (en) * | 2020-05-08 | 2020-08-11 | 徐州医科大学 | Application of GALNT2 as endometrial hyperplasia or endometrial cancer diagnosis and treatment marker |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1854313A (en) * | 2002-09-30 | 2006-11-01 | 肿瘤疗法科学股份有限公司 | Method for diagnosing non-small cell lung cancers |
| CN102061287A (en) * | 2010-11-23 | 2011-05-18 | 苏州大学 | Anti-human ppGa1NAc-T2 monoclonal antibody and application thereof |
| US20150153346A1 (en) * | 2013-11-15 | 2015-06-04 | The Regents Of The University Of Michigan | Lung cancer signature |
-
2017
- 2017-09-28 CN CN201710893999.0A patent/CN107574248A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1854313A (en) * | 2002-09-30 | 2006-11-01 | 肿瘤疗法科学股份有限公司 | Method for diagnosing non-small cell lung cancers |
| CN102061287A (en) * | 2010-11-23 | 2011-05-18 | 苏州大学 | Anti-human ppGa1NAc-T2 monoclonal antibody and application thereof |
| US20150153346A1 (en) * | 2013-11-15 | 2015-06-04 | The Regents Of The University Of Michigan | Lung cancer signature |
Non-Patent Citations (2)
| Title |
|---|
| C GU 等: "Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence", 《BRITISH JOURNAL OF CANCER》 * |
| MUHAMMAD RAMZAN MANWAR HUSSAIN 等: "N-acetylgalactosaminyltransferases in cancer", 《ONCOTARGET》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109628591A (en) * | 2018-12-04 | 2019-04-16 | 南方医科大学南方医院 | Marker for adenocarcinoma of lung prognosis prediction |
| CN109628591B (en) * | 2018-12-04 | 2022-04-15 | 南方医科大学南方医院 | Marker for prognosis prediction of lung adenocarcinoma |
| CN110618271A (en) * | 2019-09-29 | 2019-12-27 | 中国医学科学院肿瘤医院 | Method for predicting prognosis of non-small cell lung cancer |
| CN110618271B (en) * | 2019-09-29 | 2023-06-13 | 中国医学科学院肿瘤医院 | Prognosis prediction method for non-small cell lung cancer |
| CN111518890A (en) * | 2020-05-08 | 2020-08-11 | 徐州医科大学 | Application of GALNT2 as endometrial hyperplasia or endometrial cancer diagnosis and treatment marker |
| CN111518890B (en) * | 2020-05-08 | 2020-10-30 | 徐州医科大学 | Application of GALNT2 as endometrial hyperplasia or endometrial cancer diagnosis and treatment marker |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106047998A (en) | Detection method and application of lung cancer genes | |
| US20220186320A1 (en) | MicroRNA Marker Combination for Diagnosing Gastric Cancer and Diagnostic Kit | |
| Li et al. | Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas | |
| CN106834462A (en) | One group of application of stomach oncogene | |
| CN107574247A (en) | A kind of the glioblastoma auxiliary diagnosis based on CLCF1 genes, prognostic evaluation kit and its application method | |
| CN106755344A (en) | Molecular marked compound and its application for the diagnosis of cancer of pancreas clinical prognosis | |
| CN106350600A (en) | Application of LOC80054 in diagnosis or prognosis of pancreatic cancer | |
| CN107130027A (en) | Application of the biomarker in colorectal cancer | |
| CN107574248A (en) | A kind of the non-small cell lung cancer auxiliary diagnosis based on GALNT2 genes, prognostic evaluation kit and its application method | |
| CN102325902B (en) | The sample comprising colorectal cancer cell is carried out to the method and apparatus of somatotype | |
| CN102656281B (en) | For measuring the diagnostic method of nonsmall-cell lung cancer prognosis | |
| CN110229899A (en) | For colorectal cancer early diagnosis or the plasma markers object combination of prognosis prediction | |
| CN109628600A (en) | A kind of biomarker for early-stage breast cancer diagnosis | |
| CN106119347B (en) | The primer and kit of colorectal cancer transfer detection based on serum exosomal microRNAs | |
| CN109628455B (en) | Aptamer for detecting human colon cancer and application of aptamer in preparation of detection preparation | |
| CN107460251A (en) | A kind of the glioblastoma auxiliary diagnosis based on FUCA1 genes, prognostic evaluation kit and its application method | |
| CN109182528A (en) | A kind of glioblastoma auxiliary diagnosis based on ITGB5 gene, prognostic evaluation kit and its application method | |
| CN107475430A (en) | A kind of the glioblastoma auxiliary diagnosis based on IFI30 genes, prognostic evaluation kit and its application method | |
| CN106119361A (en) | The test kit detected for the NDRG4 gene methylation of early gastric caacer diagnosis and prognosis evaluation and application thereof | |
| CN110452989A (en) | Application of the biomarker in gastric cancer is detected, diagnosed | |
| CN105063029A (en) | Intrahepatic duct cell cancer related gene mutation targets and application thereof | |
| CN111575374B (en) | Molecular marker for early pancreatic tumor detection, detection method and application thereof | |
| CN106367526A (en) | Product for diagnosing prostatic cancer and application thereof | |
| CN108165546A (en) | A kind of miRNA biomarker, composition and application thereof | |
| CN109628594B (en) | One kind long-chain non-coding RNA relevant to liver cancer and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180112 |